Observational studyThe Lancet. Global health2024

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.

Kwabena Asare et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.